CSIR Central

Molecular diagnosis of Wilson disease using prevalent mutations and informative single-nucleotide polymorphism markers

Metadata of CSIR Papers

View Archive Info
 
 
Field Value
 
Title Molecular diagnosis of Wilson disease using prevalent mutations and informative single-nucleotide polymorphism markers
 
Creator Gupta, A
Maulik, M
Nasipuri, P
Chattopadhyay, I
Das, SK
Gangopadhyay, PK
Ray, K
 
Subject Medical Laboratory Technology
 
Description Background: Wilson disease (WD) is an autosomal recessive disorder caused by defects in the ATPase, Cu2+ transporting, ss-polypeptide gene (ATP7B) resulting in accumulation of copper in liver and brain. WD can be thwarted if detected at a presymptornatic stage, but occasional recombination during carrier detection with dinucleotide repeat markers flanking the WD locus may lead to faulty diagnosis. We examined the use of intragenic single-nucleotide, polymorphism (SNP) markers to avoid this limitation. Methods: We prepared genomic DNA from the peripheral blood of Indian WD patients. By use of PCR, we amplified the exons and flanking regions of the WD gene and then performed sequencing to identify the nucleotide variants. We genotyped the SNPs in 1871 individuals by use of the Sequenom mass array system. We made linkage disequilibrium plots using Haploview software. Results: We identified 1 mutation accounting for 11% (19 of 174) of WD chromosomes among patients in addition to 4 prevalent mutations characterized previously. Among 24 innocuous allelic variants identified, we selected 3 SNPs found to have high heterozygosity (> 0.40) for the detection of mutant WD chromosomes. On analyzing these SNPs in 28 test individuals, who were sibs to 17 unrelated WD patients, we obtained unequivocal genotyping in 25 cases (approximately 89%). The remaining 3 cases were genotyped by dinucleotide repeat marker (D13S133). Conclusion: Sets of SNP markers are highly heterozygous across most world populations and could be used in combination with analysis of prevalent mutations as a comprehensive strategy for determining presymptomatic and carrier sibs of WD patients. (c) 2007 American Association for Clinical Chemistry
 
Publisher AMER ASSOC CLINICAL CHEMISTRYWASHINGTON2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
 
Date 2011-09-20T12:12:32Z
2011-09-20T12:12:32Z
2007
 
Type Article
 
Identifier CLINICAL CHEMISTRY
0009-9147
http://hdl.handle.net/123456789/14313
 
Language English